At a glance
ClinicalIndex Comparison RecordN/ACompleted· 138 enrolled
Drug / intervention
desmopressindrug
Likely dose
desmopressin 0.1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Nocturin 0.1 mg Tablets in Treatment of Nocturia in Patients With Nocturnal Polyuria, Lower Urinary Tract Symptoms (LUTS) and Benign Prostate Syndrome (BPS).
In Brief
An observational study evaluating desmopressin for Nocturia Associated With Nocturnal Polyuria. Completed, enrolled 138 participants across 140 sites.
Detailed Summary
Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin (Nocturin®) 0.1 mg tablet focusing on number of nocturnal voids, ratio of night/24-h urine volume (%), duration of first undisturbed sleep period and quality of life.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedMay 2009
Primary CompletionMar 2010
TodayJul 2026
First PostedMay 15, 2009
Enrollment StartFeb 1, 2009
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.1 years ago
Interventions
desmopressindrug
desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks